Alcaftadine
An antihistamine eye drop that blocks histamine receptors in the eye and also stabilizes mast cells to prevent the release of allergy-triggering chemicals, providing rapid and sustained relief from itchy, allergic eyes. It is specifically formulated for the conjunctiva and works effectively to reduce redness, itching, and watering associated with allergic conjunctivitis.
Molekularmasse
307,4000 g/mol
LogP
1,70
TPSA
38,10 Ų
Lipinski-Regel der Fünf
Bestanden
Wirkmechanismus
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1
InChI
InChI=1S/C19H21N3O/c1-21-9-6-15(7-10-21)18-17-5-3-2-4-14(17)8-11-22-16(13-23)12-20-19(18)22/h2-5,12-13H,6-11H2,1H3
Molecular Formula
C19H21N3O
HBD / HBA
- / 3
Rotierbare Bindungen
1
Schwere Atome
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
An antihistamine eye drop that blocks histamine receptors in the eye and also stabilizes mast cells to prevent the release of allergy-triggering chemicals, providing rapid and sustained relief from itchy, allergic eyes. It is specifically formulated for the conjunctiva and works effectively to reduce redness, itching, and watering associated with allergic conjunctivitis.
Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.
Yes, Alcaftadine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201747. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 19371515. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="alcaftadine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/alcaftadine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/alcaftadine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/alcaftadine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="alcaftadine"></drugfyi-drug>